BioVie to Host Live Investor Webinar and Q&A on Oct. 8
BioVie (NASDAQ: BIVI), a clinical-stage biotech company, will host an investor webinar on October 8, 2025, at 4:15 p.m. ET. CEO Cuong Do will present updates on two key drug candidates: bezisterim (NE3107), targeting Alzheimer's, Parkinson's, and long COVID, and BIV201 for refractory ascites in liver cirrhosis.
The presentation will highlight bezisterim's role in addressing inflammation and insulin resistance, with clinical studies showing promising results in cognition and motor function improvement. BIV201, their late-stage orphan drug candidate, targets a condition with no current FDA-approved therapies. The company will discuss ongoing clinical programs and potential partnership opportunities.
BioVie (NASDAQ: BIVI), una società biofarmaceutica in fase clinica, terrà un webinar per investitori lunedì 8 ottobre 2025 alle 16:15 ora ET. Il CEO Cuong Do presenterà aggiornamenti su due candidati chiave: bezisterim (NE3107), mirato ad Alzheimer, Parkinson e long COVID, e BIV201 per ascite refrattaria nella cirrosi epatica.
La presentazione evidenzierà il ruolo di bezisterim nel contrastare l'infiammazione e la resistenza all'insulina, con studi clinici che mostrano risultati promettenti su cognizione e funzione motoria. BIV201, loro candidato orfano in fase avanzata, mira a una condizione per la quale non esistono terapie approvate dalla FDA al momento. L'azienda discuterà i programmi clinici in corso e le potenziali opportunità di partnership.
BioVie (NASDAQ: BIVI), una compañía biotecnológica en etapa clínica, organizará un seminario web para inversores el 8 de octubre de 2025 a las 16:15 ET. El CEO Cuong Do presentará actualizaciones sobre dos candidatos clave: bezisterim (NE3107), dirigido a Alzheimer, Parkinson y long COVID, y BIV201 para ascitis refractaria en la cirrosis hepática.
La presentación destacará el papel de bezisterim en el abordaje de la inflamación y la resistencia a la insulina, con estudios clínicos que muestran resultados prometedores en cognición y función motora. BIV201, su candidato de fármaco huérfano en fase avanzada, aborda una condición para la que actualmente no existen terapias aprobadas por la FDA. La empresa discutirá los programas clínicos en curso y posibles oportunidades de asociación.
BioVie (NASDAQ: BIVI), 임상 단계의 바이오제약 회사는 2025년 10월 8일 오후 4시 15분 ET에 투자자 웨비나를 개최합니다. CEO Cuong Do가 두 가지 핵심 후보 물질에 대한 업데이트를 발표합니다: bezisterim (NE3107)은 알츠하이머, 파킨슨병 및 롱 코로나를 대상으로 하며, BIV201은 간경화로 인한 난치성 복수에 대한 후보 물질입니다.
발표는 bezisterim이 염증과 인슐린 저항성을 다루는 역할에 초점을 맞추고, 인지 기능 및 운동 기능 개선에 대한 임상 연구에서 유망한 결과를 보여준다고 강조합니다. 고령의 희귀의약품 후보인 BIV201은 현재 FDA 승인 치료제가 없는 상태의 질환을 목표로 합니다. 회사는 진행 중인 임상 프로그램과 잠재적 파트너십 기회에 대해 논의할 예정입니다.
BioVie (NASDAQ: BIVI), une société biotechnologique en phase clinique, organisera un webinar pour investisseurs le 8 octobre 2025 à 16h15 ET. Le PDG Cuong Do présentera des mises à jour sur deux candidats phares : bezisterim (NE3107), visant l’Alzheimer, la maladie de Parkinson et le long COVID, et BIV201 pour l’ascite réfractaire liée à la cirrhose hépatique.
La présentation mettra en évidence le rôle de bezisterim dans le traitement de l’inflammation et de la résistance à l’insuline, avec des études cliniques montrant des résultats prometteurs en cognition et en fonction motrice. BIV201, leur candidat médicament orphelin en phase avancée, cible une maladie pour laquelle il n’existe actuellement aucun traitement approuvé par la FDA. L’entreprise discutera des programmes cliniques en cours et des opportunités de partenariat potentielles.
BioVie (NASDAQ: BIVI), ein klinisch relevantes Biotech-Unternehmen, wird einen Investoren-Webinar am 8. Oktober 2025 um 16:15 Uhr ET abhalten. CEO Cuong Do wird Updates zu zwei Schlüssel-Kandidaten präsentieren: bezisterim (NE3107), der auf Alzheimer, Parkinson und Long COVID abzielt, und BIV201 für refraktäre Aszites bei Leberzirrhose.
Die Präsentation wird bezisterims Rolle bei der Behandlung von Entzündungen und Insulinresistenz hervorheben, wobei klinische Studien vielversprechende Ergebnisse bei Kognition und motorischer Funktion zeigen. BIV201, ihr fortgeschrittener Orphan-Drug-Kandidat, zielt auf eine Erkrankung ab, für die es derzeit keine FDA- zugelassenen Therapien gibt. Das Unternehmen wird laufende klinische Programme und potenzielle Partnerschaftsmöglichkeiten diskutieren.
BioVie (بورصة NASDAQ: BIVI)، شركة تكنولوجيا حيوية في مرحلة إكلينيكية، ستعقد وبينار للمستثمرين في 8 أكتوبر 2025 الساعة 4:15 مساءً بتوقيت شرق الولايات المتحدة. سيقدم الرئيس التنفيذي كوونغ دو تحديثات حول مرشحي الدواء الرئيسيين: bezisterim (NE3107)، المستهدف للزهايمر ومرض باريتونز والتهاب كوفيد الطويل، وBIV201 للحالة المرتبطة بالاستسقاء المعوي في تليف الكبد.
ستبرز العرض دور bezisterim في معالجة الالتهاب ومقاومة الأنسولين، مع نتائج واعدة للوظائف الإدراكية والحركية في الدراسات السريرية. بيف201، مرشحهم الدوائي اليتيم في المراحل الأخيرة، يستهدف حالة لا توجد لها علاجات معتمدة من FDA في الوقت الحالي. ستناقش الشركة البرامج السريرية الجارية وفرص الشراكة المحتملة.
BioVie（纳斯达克股票代码：BIVI），一家处于临床阶段的生物科技公司，将于2025年10月8日东部时间下午4:15举行投资者网络研讨会。CEO Cuong Do 将介绍两个关键药物候选药物的最新进展：bezisterim（NE3107），针对阿尔茨海默病、帕金森病和长期新冠，及BIV201用于肝硬化合并难治性腹水。
本次演讲将强调 bezisterim 在炎症和胰岛素抵抗方面的作用，临床研究显示在认知和运动功能方面有良好前景。BIV201 作为他们的晚期孤儿药候选，针对当前尚无 FDA 批准治疗的病症。公司将讨论正在进行的临床计划和潜在的合作机会。
- None.
- None.
CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, will host an investor webinar at 4:15 p.m. ET on Wednesday, Oct. 8, 2025.
The exclusive event, hosted by RedChip Companies, will feature Cuong Do, president and CEO of BioVie, who will discuss bezisterim (NE3107), the company’s first-in-class, orally available small molecule that targets inflammation and insulin resistance, two key drivers of Alzheimer’s, Parkinson’s, and long COVID. Clinical studies have shown encouraging signals of improved cognition, motor function and reduced neuroinflammation. Do will also outline progress with BIV201, BioVie’s late-stage orphan drug candidate for refractory ascites, a life-threatening complication of liver cirrhosis that currently has no FDA-approved therapies.
With several late-stage clinical programs underway and supportive safety data, BioVie is advancing toward key milestones and evaluating potential partnerships in markets with significant commercial potential.
A live Q&A session with management will follow the presentation.
To register for the free webinar, please visit: https://www.redchip.com/webinar/BIVI/87879092882
Questions can be pre-submitted to BIVI@redchip.com or online during the live event.
About BioVie, Inc.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease and long COVID) and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-κB, and the associated neuroinflammation and insulin resistance but not ERK and NFκB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease and Parkinson’s disease. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BIVI@redchip.com
Chuck Padala
Managing Director
LifeSci Advisors, LLC
chuck@lifesciadvisors.com
FAQ
When is BioVie (BIVI) hosting its investor webinar and how can investors attend?
What drug candidates will BioVie (BIVI) discuss during the October 2025 webinar?
What are the key features of BioVie's bezisterim (NE3107) drug candidate?
What is BioVie's BIV201 drug candidate targeting?
Who will be presenting at BioVie's October 2025 investor webinar?
